EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] post-marketing surveillance in Japan
The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.
- Patients who have been determined to start EYLEA treatment - Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858) - Patients who have agreed with the patient informed consent
- Patients who have already received EYLEA
Many Locations, Japan
E-mail: [email protected]
Phone: 49 30 300139003
Special Drug Use Investigation of EYLEA for Quality of Life